The estimated Net Worth of Fred Kurland is at least 226 千$ dollars as of 4 May 2023. Mr Kurland owns over 4,000 units of Aridis Pharmaceuticals Inc stock worth over 4$ and over the last 20 years he sold ARDS stock worth over 0$. In addition, he makes 226,188$ as Consultant at Aridis Pharmaceuticals Inc.
Mr has made over 12 trades of the Aridis Pharmaceuticals Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 4,000 units of ARDS stock worth 4$ on 4 May 2023.
The largest trade he's ever made was exercising 29,938 units of Aridis Pharmaceuticals Inc stock on 6 April 2015 worth over 30$. On average, Mr trades about 6,004 units every 232 days since 2004. As of 4 May 2023 he still owns at least 4,000 units of Aridis Pharmaceuticals Inc stock.
You can see the complete history of Mr Kurland stock trades at the bottom of the page.
Fred Kurland is the Consultant at Aridis Pharmaceuticals Inc.
As the Consultant of Aridis Pharmaceuticals Inc, the total compensation of Mr Kurland at Aridis Pharmaceuticals Inc is 226,188$. There are 1 executives at Aridis Pharmaceuticals Inc getting paid more, with Dr. Vu L. Truong having the highest compensation of 566,125$.
Mr Kurland is 69, he's been the Consultant of Aridis Pharmaceuticals Inc since . There are 2 older and 3 younger executives at Aridis Pharmaceuticals Inc. The oldest executive at Aridis Pharmaceuticals Inc is Dr. Eric J. Patzer, 71, who is the Exec. Chairman.
Fred's mailing address filed with the SEC is C/O ARIDIS PHARMACEUTICALS, INC., 983 UNIVERSITY AVENUE, BLDG. B, LOS GATOS, CA, 95032.
Over the last 6 years, insiders at Aridis Pharmaceuticals Inc have traded over 0$ worth of Aridis Pharmaceuticals Inc stock and bought 1,445,847 units worth 181,502$ . The most active insiders traders include Vu Truong、Eric Patzer、Fred Kurland. On average, Aridis Pharmaceuticals Inc executives and independent directors trade stock every 89 days with the average trade being worth of 125$. The most recent stock trade was executed by Eric Patzer on 24 June 2024, trading 714,286 units of ARDS stock currently worth 50,000$.
aridis is a privately held infectious diseases focused company in san jose, ca, usa. aridis’ advanced formulation and delivery technologies are combined with proprietary products portfolio to create potent drug candidates that are packaged into convenient to administer, "ready-to-use" formats.
Aridis Pharmaceuticals Inc executives and other stock owners filed with the SEC include: